PharmaNetics Inc.

The new model aims to capture drug-like revenues and margins without taking drug-like development and regulatory risk. By Ellen Foster Licking and Roger Longman Diagnostics have had an image problem f

VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business mod

The Vioxx situation raises an inevitable question as Pharma looks to improve R&D efficiency and clinical utility: What is the role of pharmacogenomics in assessing the safety and efficacy of primary c

The complexity of treatment regimens and the rapid dissemination of data give marketers opportunities to educate, and potentially, to obfuscate. by Mark L. Ratner The second of a two-part series. Prac